



**Anti-Hemophilic  
Antithrombin III (Recombinant) J7196  
Antithrombin III (Human) 1IU J7197  
Prior Authorization Request  
Medicare Part B Form**

*Instructions: \* Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.*

<input type="checkbox"/>	<b>NEW START - Start Date:</b> _____	<input type="checkbox"/>	<b>Continuation</b> (within 365 days): Date of last treatment _____
<input type="checkbox"/>	Date Requested _____		
	Requestor _____ Clinic name: _____ Phone _____ / Fax _____		

**MEMBER INFORMATION**

\*Name: \_\_\_\_\_ \*ID#: \_\_\_\_\_ \*DOB: \_\_\_\_\_

**PRESCRIBER INFORMATION**

\*Name: \_\_\_\_\_  MD  FNP  DO  NP  PA \*Phone: \_\_\_\_\_

\*Address: \_\_\_\_\_ \*Fax: \_\_\_\_\_

**DISPENSING PROVIDER / ADMINISTRATION INFORMATION**

\*Name: \_\_\_\_\_ Phone: \_\_\_\_\_

\*Address: \_\_\_\_\_ Fax: \_\_\_\_\_

**PROCEDURE / PRODUCT INFORMATION**

HCPC Code	Name of Drug <input type="checkbox"/> Self-administered	Dose (Wt: _____ kg Ht: _____ )	Frequency	End Date if known

Chart notes attached. **Other important information:** \_\_\_\_\_

**Diagnosis: ICD10:** \_\_\_\_\_ **Description:** \_\_\_\_\_

Provider attests the diagnosis provided is an FDA-Approved indication for this drug

**CLINICAL INFORMATION**

New Start or Initial Request: (Clinical documentation required for all requests)  
 **Provider has reviewed the attached “Criteria for Approval” and attests the member meets ALL required PA criteria.**  
 If not, please provide **clinical rationale** for formulary exception: \_\_\_\_\_

Continuation Requests: (Clinical documentation required for all requests)  
 **Provider has reviewed the attached “Criteria for Continuation” and attests the member meets ALL required PA Continuation criteria.**  
 Patient had an adequate response or significant improvement while on this medication.  
 If not, please provide clinical rationale for continuing this medication: \_\_\_\_\_

**ACKNOWLEDGEMENT**

**Request By (Signature Required):** \_\_\_\_\_ **Date:** \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties. **THIS AUTHORIZATION IS NOT A GUARANTEE OF PAYMENT.** PAYMENT IS BASED ON BENEFITS IN EFFECT AT THE TIME OF SERVICE, MEMBER ELIGIBILITY AND MEDICAL NECESSITY.

**Prior Authorization Group – Coagulation Factors PA**

**Drug Name(s):**

**ANTITHROMBIN III (Human)**

**ANTITHROMBIN III (Recombinant)**

**Criteria for approval of Non-Formulary/Preferred Drug:**

1. Prescribed for an approved FDA diagnosis (as listed below):
2. Patient is being treated for ONE of the following purposes:
  - a. Treatment and prevention of thromboembolism
  - b. Prevention of perioperative and peripartum thromboembolism
3. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
  - If the member meets all these criteria, they may be approved by the Plan for the requested drug.
  - Quantity limits and Tiering will be determined by the Plan.

**Exclusion Criteria:**

N/A

**Age Restrictions:**

N/A

**Prescriber Restrictions:**

N/A

**FDA Indications:**

**Antithrombin III (Human/Recombinant):**

- Treatment of hereditary antithrombin III deficiency
  - Treatment and prophylaxis of thromboembolic disorder
  - Prophylaxis of perioperative and peripartum thromboembolic disorder

**Off-Label Uses:**

- Antithrombin III deficiency, Acquired
- Drug resistance, Heparin

**Coverage Duration:**

**Approval will be for 12 months**

**Other Clinical Consideration:**

N/A

**Resources:**

[https://www.micromedexsolutions.com/micromedex2/librarian/CS/4CBAB6/ND\\_PR/evidencexpert/ND\\_P/evidencexpert/DUPLICATIONSHIELDSYNC/72545D/ND\\_PG/evidencexpert/ND\\_B/evidencexpert/ND\\_AppProduct/evidencexpert/ND\\_T/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=Antithrombin%20III%20\(Human\)&UserSearchTerm=Antithrombin%20III%20\(Human\)&SearchFilter=filterNone&navitem=searchGlobal#](https://www.micromedexsolutions.com/micromedex2/librarian/CS/4CBAB6/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/72545D/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=Antithrombin%20III%20(Human)&UserSearchTerm=Antithrombin%20III%20(Human)&SearchFilter=filterNone&navitem=searchGlobal#)